Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | GPR6 | P46095 | 13/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | GRM5 | P41594 | 1/20 | 0.33 |
| ▸ | HSP90AB1 | P08238 | 2/20 | 0.32 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4204506 | 0.86 | NPSR1 (0.38) | SMN1; SMN2GAAMAPTHSP90AA1NPC1 | |
| SCHEMBL4009886 | 0.86 | FABP3 (0.37) | SMN1; SMN2GAAMAPTCYP2C9HSP90AB1 | |
| SCHEMBL4204508 | 0.84 | WHR1 (0.35) | GRM5HSP90AB1HSP90AA1NPC1RAB9A | |
| SCHEMBL4014837 | 0.77 | HTR6 (0.36) | LMNASMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL4212997 | 0.76 | HTR6 (0.36) | — | |
| SCHEMBL8044950 | 0.71 | USP2 (0.47) | SMN1; SMN2MAPT | |
| SCHEMBL8057043 | 0.69 | MAPT (0.42) | MAPT | |
| SCHEMBL4214586 | 0.68 | USP2 (0.43) | SMN1; SMN2MAPT | |
| SCHEMBL28745137 | 0.66 | KEAP1 (0.41) | SMN1; SMN2GRM5HSP90AB1HSP90AA1 | |
| SCHEMBL27931611 | 0.65 | NCF1 (0.36) | LMNASMN1; SMN2MAPTCYP2C19NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090312306-A1 | TETRAHYDRO-5H-PYRIDO[2,3-D]AZEPINES AS 5-HT2C LIGANDS | CASCADE THERAPEUTICS INC. (CA) | 2009-12-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090312306-A1 | TETRAHYDRO-5H-PYRIDO[2,3-D]AZEPINES AS 5-HT2C LIGANDS | HTR2C, HTR2A, HTR5A | LMNA 3569/4885SMN1; SMN2 965/4885GPR6 215/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.